Invention Grant
- Patent Title: Indazole-3-carboxamides and their use as WNT/B-catenin signaling pathway inhibitors
-
Application No.: US16576308Application Date: 2019-09-19
-
Publication No.: US11066388B2Publication Date: 2021-07-20
- Inventor: John Hood , Sunil Kumar KC
- Applicant: BioSplice Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: BioSplice Therapeutics, Inc.
- Current Assignee: BioSplice Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Fish & Richardson P.C.
- Main IPC: A61K31/416
- IPC: A61K31/416 ; A61P35/00 ; C07D401/14 ; A61K45/06 ; C07D401/10 ; C07D405/14 ; C07D413/12 ; C07D401/04 ; C07D401/12

Abstract:
Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Public/Granted literature
- US20200239436A1 INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS Public/Granted day:2020-07-30
Information query
IPC分类: